$13.39 4.8%
ADMA Stock Price vs. AI Score (Last 150 days)
Data gathered: July 16

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

ADMA Biologics
Price $13.39
Target Price Sign up
Volume 4,110,000
Market Cap $3.1B
Year Range $3.62 - $13.39
Dividend Yield 0%
Revenue per Employee $458,957
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2482M43M39M18M24M0.080
Q4 '2374M43M31M-18M16M-0.080
Q3 '2367M43M25M2.6M11M0.010
Q2 '2360M43M17M-6.4M1.6M-0.030
Q1 '2357M40M17M-6.8M1.2M-0.030

Insider Transactions View All

Grossman Adam S filed to sell 2,081,475 shares at $10.7.
June 14 '24
ELMS STEVE filed to sell 2,115,671 shares at $6.1.
March 19 '24
ELMS STEVE filed to sell 2,527,500 shares at $6.
March 19 '24
ELMS STEVE filed to sell 2,577,387 shares at $6.
March 15 '24
ELMS STEVE filed to sell 2,760,395 shares at $6.1.
March 15 '24

What is the Market Cap of ADMA Biologics?

The Market Cap of ADMA Biologics is $3.1B.

How Many People Work at ADMA Biologics?

As of our latest update, ADMA Biologics employed approximately 617 people worldwide. However, it's important to note that ADMA Biologics' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is ADMA Biologics' revenue per employee?

$458,957. To calculate ADMA Biologics' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of ADMA Biologics?

Currently, the price of one share of ADMA Biologics stock is $13.39.

How can I analyze the ADMA stock price chart for investment decisions?

The ADMA stock price chart above provides a comprehensive visual representation of ADMA Biologics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ADMA Biologics shares. Our platform offers an up-to-date ADMA stock price chart, along with technical data analysis and alternative data insights.

Does ADMA offer dividends to its shareholders?

As of our latest update, ADMA Biologics (ADMA) does not offer dividends to its shareholders. Investors interested in ADMA Biologics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of ADMA Biologics?

Some of the similar stocks of ADMA Biologics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.